**RESULTS**

**Effect of Combined Treatment of ARQ 092 with Anti-PD-1 Antibody on Syngeneic Mouse Tumor Model**

The combination of ARQ 092 with anti-PD-1 antibody enhances antitumor activity in comparison to the single agents in the CT-26 model. Tumor growth was assessed over a period of 26 days. The CI values were calculated using the Combination Indices Interpretation method.

**Anti-Tumor Activity of Combined Treatment of ARQ 092 and Paclitaxel in Xenograft Models**

The combination of ARQ 092 with paclitaxel exerts enhanced antitumor activity in breast cancer cell lines with activated PD-1/PD-L1.

**Combination of ARQ 092 and ARQ 531, a BTK inhibitor, is Superior to Single Agents**

Dual inhibition of AKT and BTK pathways may exert superior response to single pathway inhibition.

**ACKNOWLEDGMENTS**

- Yi Yu, Terence Hall, Sudharshan Eathiraj, Ronald E. Savage, and Brian Schwartz

**REFERENCES**

- ArQule, Inc., Burlington, MA

**CONCLUSIONS**

- Combination of miransertib (ARQ 092) with an immune checkpoint inhibitor exhibits enhanced antitumor activity in syngeneic mouse tumor models.
- Miransertib exhibits superior anti-tumor activity in xenograft models with cancer cells or in patient-derived tumor cells when combined with paclitaxel, HER2 antagonists or MEK inhibitor.
- Combination of miransertib with the BTK inhibitor, ARQ 531, shows superior anti-proliferative effect in comparison to single agents in vitro and antitumor activity in xenograft models.

**Support**

- A phase II clinical study of miransertib in combination with anastrozole in a molecularly defined patient population, is ongoing (NCT02470355).